898746-35-5

Usage

Uses

Used in Pharmaceutical Industry:
1H-PYRROLO[2,3-B]PYRIDINE-6-CARBOXYLIC ACID is used as a building block for the synthesis of biologically active molecules, contributing to the development of new drugs and therapeutic agents.
Used in Coordination Chemistry:
1H-PYRROLO[2,3-B]PYRIDINE-6-CARBOXYLIC ACID is used as a ligand, playing a crucial role in the formation of coordination compounds, which have applications in various fields such as catalysis, materials science, and medicinal chemistry.
Used in Organic Synthesis:
1H-PYRROLO[2,3-B]PYRIDINE-6-CARBOXYLIC ACID is used as a precursor in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications in industries such as pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 189882-33-5 1H-pyrrolo[2,3-b]pyridine-6-carbonitrile 
• 143468-13-7 6-Bromo-1H-pyrrolo<2,3-b>pyridine 

Downstream Products

• 1638763-49-1 methyl 3-iodo-1H-pyrrolo[2,3-b]pyridine-6-carboxylate 
• 1227268-70-3 methyl 2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-6-carboxylate 
• 1263413-97-3 1H-pyrrolo[2,3-b]pyridin-6-ylmethanol 

Relevant academic research and scientific papers

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

6-carboxylic acid methyl ester-2-oxo-7-azaindoles and its preparation method and application

The invention relates to 6-carboxylmethyl-2-oxo-7-azaindole as shown in the formula (I) in the specification and also relates to a preparation method and application of 6-carboxylmethyl-2-oxo-7-azaindole. According to the preparation method, 6-carboxylmethyl-2-oxo-7-azaindole is prepared by taking 6-cyano-7-azaindole as a raw material through the four reaction steps of hydrolysis of a cyano group, methyl esterification of carboxylic acid, bromine oxidization and reduction. The method is simple and convenient to operate, the raw material is easily obtained, and the yield is high. As a key intermediate, 6-carboxylmethyl-2-oxo-7-azaindole opens a new unique approach for preparing a final product with biological activity. Particularly, a product with the purity of higher than 98% can be obtained by using the preparation method provided by the invention, so that the large-scale continuous production for synthesizing the final product can be realized.

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS

The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free form or in pharmaceutically acceptable salt form, to their preparation, to their medical use and to medicaments comprising them.